Over the past several years, few issues have generated as much uncertainty in workplace drug and alcohol testing as marijuana. What was once a relatively straightforward compliance topic has evolved into a complex intersection of federal regulation, state legalization, scientific limitations, and emerging technology. Employers, particularly those responsible for safety-sensitive operations are often left sorting through headlines, assumptions, and misinformation while still being held to strict regulatory standards.
As we move into another month, it is important to pause and clarify where things truly stand. Federal marijuana policy is changing, but not in the way many people assume. Non-DOT testing programs are evolving, but with important limitations. And at the same time, new technologies like marijuana breath testing are emerging to address longstanding gaps in traditional testing methods. Understanding how these developments fit together is critical for maintaining both compliance and safety.
Executive Order Reclassifying Marijuana
In December 2025, marijuana policy reached a pivotal moment at the federal level. On December 18, the President of the United States issued an Executive Order directing the Department of Justice to complete the rescheduling process of marijuana from a Schedule I drug to a Schedule III drug under the Controlled Substances Act. This announcement immediately prompted questions from employers, service agents, and regulated employees alike, especially those operating under Department of Transportation authority. https://www.transportation.gov/odapc/marijuana-notice
In response to the surge of inquiries, the Department of Transportation’s Office of Drug and Alcohol Policy and Compliance (ODAPC) issued a formal notice to clarify the impact of the Executive Order on DOT drug testing requirements. The guidance was direct and intentional, designed to remove ambiguity rather than create it.
Department of Transportation Clarifies
First and foremost, the DOT emphasized that marijuana remains a Schedule I drug under the Controlled Substances Act until the rescheduling process is fully completed. The Executive Order does not, by itself, change marijuana’s legal status. As a result, marijuana use remains unacceptable for any safety-sensitive employee subject to DOT drug testing regulations. This includes pilots, truck drivers, school bus drivers, train engineers, subway operators, aircraft maintenance personnel, transit armed security staff, ship captains, and pipeline emergency response personnel, among others.
Second, and equally important, the DOT made it clear that its drug testing regulations are not changing at this time. Until the rescheduling process is completed and unless formal regulatory amendments are adopted, DOT drug testing procedures remain exactly as they are today. DOT safety-sensitive transportation employees will continue to be tested for marijuana, and a verified positive THC result will continue to carry the same consequences it always has.
Medical and Recreational Marijuana Guidance
The DOT also reaffirmed that its existing guidance on medical marijuana, recreational marijuana, and CBD remain fully in effect. In other words, there are no exceptions created by state law, medical authorization, or consumer hemp products when it comes to DOT-regulated testing. Federal rules override state legalization in safety-sensitive transportation roles, and employers are still required to enforce those rules consistently.
For laboratories, Medical Review Officers, and Substance Abuse Professionals, the message was equally clear. All service agents must continue to follow 49 CFR Part 40 without deviation. There are no changes to professional roles, responsibilities, verification standards, or return-to-duty processes related to marijuana. The DOT concluded its notice by assuring the transportation industry and the traveling public that safety remains its highest priority and that it will continue to monitor the rescheduling process and provide updates as appropriate.
Non-Regulated Testing Guidelines
While DOT-regulated testing remains stable and unchanged, the Non-DOT testing landscape tells a different story. Outside of DOT authority, employers operate under a combination of company policy, state law, and federal guidance from agencies such as the Department of Health and Human Services. In this space, gradual changes are taking place, particularly in how THC is described, analyzed, and understood from a scientific standpoint.
HHS has recently updated laboratory guidelines to refine THC analyte terminology, aligning test reporting with modern analytical science. These changes do not alter test outcomes or thresholds, but they reflect an industry that is modernizing its language and methodology. HHS has also continued to allow greater laboratory flexibility through biomarker testing, expanding the analytical tools available for Non-DOT drug testing programs.
For employers, these updates highlight a broader shift. Non-DOT testing is increasingly expected to balance compliance with fairness, safety, and scientific relevance. This balancing act is not always easy, especially when it comes to marijuana.
Marijuana Testing Methods and New Technology
Traditional marijuana testing, particularly urine testing, has a well-documented limitation: it detects prior use, not current impairment. THC metabolites can remain detectable in the body long after any psychoactive effects have ended. An employee could test positive days or even weeks after use, despite being completely unimpaired at the time of testing. While this approach has long been accepted under DOT rules, it presents challenges for Non-DOT employers operating in states where marijuana use is legal outside of work.
This disconnect often places employers in a difficult position. On one hand, they are responsible for maintaining a safe workplace. On the other, they may face legal, cultural, or employee relations challenges when enforcing policies that rely on testing methods disconnected from real-time impairment. Furthermore, employers face challenges as it relates to hiring and maintaining a strong, able, and healthy workforce. As marijuana legalization continues to expand, these tensions are becoming more pronounced.
Detect Impairment, Not Metabolites
This is where marijuana breath testing enters the conversation, and why it is increasingly viewed as a meaningful advancement rather than a novelty.
The Cannabix Marijuana Breath Test (MBT) represents a fundamentally different approach to marijuana testing or THC detection. Rather than identifying long-lasting metabolites in urine or hair, breath testing targets delta-9-THC present in breath aerosols shortly after consumption. The detection window is measured in hours, making it far more relevant to identifying recent use that could impact safety or performance.
From a workplace perspective, this distinction matters. Employers are not attempting to regulate lawful off-duty behavior. Although the MBT measures detection and not impairment, employers have concern whether an individual may have marijuana in their system from recent use while performing job duties, especially in environments where a lapse in judgment can lead to serious injury, property damage, or loss of life. Breath testing aligns more closely with that objective.
The Cannabix MBT also offers practical and operational advantages. Breath collection is non-invasive and familiar, modeled after alcohol breath testing that has been widely accepted for decades. The system includes features designed to support accuracy and defensibility, including ambient air sampling and dual breath collection to help eliminate environmental contamination concerns.
Importantly, the MBT is not a point-of-guesswork device. Breath samples are analyzed using laboratory-based analytical methods, preserving chain-of-custody integrity and supporting results that can withstand regulatory and legal scrutiny. Cannabix has partnered with established forensic laboratories to support validation and commercialization, signaling that the technology is being developed with real-world workplace and compliance environments in mind.
For Non-DOT employers, marijuana breath testing can serve as a valuable complement to existing testing programs. It may be particularly useful in reasonable suspicion and post-incident situations, where determining recent use is far more relevant than identifying historical exposure. While breath testing does not replace DOT-mandated urine or oral fluid testing, it fills an important gap that traditional testing methods simply cannot address.
Even within the DOT-regulated world, marijuana breath testing holds long-term significance. As policymakers continue to examine impairment standards and testing science, breath-based THC detection mirrors the framework that has successfully governed alcohol testing for years. Although DOT has not authorized marijuana breath testing at this time, technologies like the Cannabix MBT help shape the future conversation around impairment-based testing.
Monitoring the Landscape
At its core, the current marijuana testing landscape demands clarity and realism. Despite widespread headlines about rescheduling, DOT marijuana testing requirements remain firmly in place. Compliance expectations have not softened, and employers must continue to enforce them consistently. At the same time, Non-DOT testing programs are evolving, driven by scientific advancement, legal complexity, and a growing emphasis on relevance and fairness.
As these dynamics continue to unfold, marijuana breath testing represents a forward-looking solution, one that focuses on recent use, supports safety objectives, and reflects modern scientific understanding. For employers committed to protecting their workforce, their customers, and the public, staying informed and prepared is not optional.
We will continue to monitor federal developments closely, track changes in both DOT and Non-DOT guidance, and evaluate emerging technologies that support safer, more defensible testing programs. As always, our goal is to help you navigate change with confidence while maintaining the highest standards of safety and compliance.
To learn more about the Cannabix MBT, visit our website or contact us today!